Press Releases

    Print Page  Close Window
BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today that it has entered into a new ten-year lease with Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) encompassing approximately 148,000 square feet at The Landmark at Eastview campus in Tarrytown, New York. This new lease replaces existing leases with Progenics which were set to expire from 2009 to 2012.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091005/BIOMEDLOGO)

According to Alan D. Gold, BioMed's Chairman and Chief Executive Officer, "We are very pleased with our expanding relationship with Progenics, one of BioMed's premier large, publicly traded life science tenants. We look forward to further supporting their efforts to continue discovery for treatment of patients with debilitating conditions and life-threatening disease, with principle programs directed toward supportive care, virology and oncology."

Paul J. Maddon, M.D., Ph.D., Progenics' Founder, Chief Executive Officer and Chief Science Officer, remarked, "Landmark's state-of-the-art research facilities have allowed Progenics to expand our presence in Westchester County in order to develop and commercialize our innovative therapeutic products. The Landmark campus is the ideal collaborative environment to support our research and growth."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 114 buildings with approximately 10.5 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

About Progenics

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward supportive care, virology -- including human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections -- and oncology. Progenics is developing RELISTOR(R) (methylnaltrexone bromide) for the treatment of opioid-induced side effects. RELISTOR is currently approved in over 30 countries, including the U.S. and E.U. member countries, Canada, Australia, and Brazil; marketing applications are pending elsewhere throughout the world. Progenics' former collaborator, Wyeth Pharmaceuticals, is continuing manufacturing, sales, marketing, distribution and certain development, clinical and regulatory activities during an approximately one-year transition after the October 2009 termination of their 2005 RELISTOR collaboration. In Japan, Ono Pharmaceutical Co., Ltd. has an exclusive license from Progenics for development and commercialization of subcutaneous RELISTOR in that country. In the U.S., RELISTOR subcutaneous injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. In the area of virology, Progenics is developing the HIV-entry inhibitor PRO 140, a humanized monoclonal antibody which binds to co-receptor CCR5 to inhibit HIV entry. PRO 140 is currently in phase 2 clinical testing for the treatment of HIV infection. The Company also has an HCV discovery program to identify novel inhibitors of HCV entry. In the area of oncology, the Company is conducting a phase 1 clinical trial of a human monoclonal antibody-drug conjugate (ADC) for the treatment of prostate cancer -- a selectively targeted chemotherapeutic antibody directed against prostate-specific membrane antigen (PSMA). PSMA is a protein found on the surface of prostate cancer cells as well as in blood vessels supplying other solid tumors. Progenics is also conducting phase 1 clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA. For more information about Progenics Pharmaceuticals, Inc., please visit www.progenics.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.

Rick Howe, Director, Corporate Communications, of BioMed Realty Trust, Inc., +1-858-207-5859, richard.howe@biomedrealty.com